Acutaas Chemicals Ltd · 543349
—
—
—
—
—
₹152 Cr
₹186 Cr
₹154 Cr
₹172 Cr
₹166 Cr
₹225 Cr
₹177 Cr
₹247 Cr
₹275 Cr
₹308 Cr
₹207 Cr
₹306 Cr
₹393 Cr
₹433 Cr
₹330 Cr
20-quarter listed-company comparison
Pharma - API & CRAMS Stocks in India
Pharma - API & CRAMS: Divis Laboratories Ltd owns the largest revenue base; Neuland Laboratories Ltd has the fastest current growth.
01 · the index people search for
Nifty Pharma - API & CRAMS Index — Constituents & Performance
The Pharma - API & CRAMS companies below are the listed Indian Pharma - API & CRAMS universe this page tracks — the same constituent set people search for as the Nifty Pharma - API & CRAMS index. Every figure is equal-weighted across those companies, so one large constituent cannot set the reading. Each number carries its own as-of date.
02 · the sector itself · before any single company
How has Pharma - API & CRAMS moved against NIFTY 500?
The line below covers up to 5.2 years and opens on the 5Y view; the buttons cut it shorter. Over the most recent two of them this sector is 56% ahead of NIFTY 500. Earnings across its companies grew 14% on average over the last four reported quarters. It has been ahead of NIFTY 500 on a rolling three-month view for 18 weeks running.
LEADER · ahead 18w~Price and the fundamentals both up16 of 24 companies ahead of NIFTY 500 by 5% or more over three months
RS ↑18w · 18/24 >200d (−3) · 16/24 lead (−5) · EPS 14/24↑
Pharma - API & CRAMS, equal-weighted, based at 200
NIFTY 500, same base, same start
trailing 12-month earnings per share rising
falling
Pharma - API & CRAMS, equal-weighted, based at 200
NIFTY 500, same base, same start
trailing 12-month earnings per share rising
falling
Pharma - API & CRAMS, equal-weighted, based at 200
NIFTY 500, same base, same start
trailing 12-month earnings per share rising
falling
Both lines start at 200 in the same week, so the distance between them is the whole story: the sector line is an equal-weighted index of its 24 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member rebased to 100 at the start and the sector taking the median — so a price line pulling away from flat bars is a re-rating, not earnings. A bar turns red when that figure is lower than the quarter before. Rules are fixed and applied identically everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover any point to read both values and the gap. This is a description of what the numbers did, not advice.
03 · sector relative strength, before individual stocks
Is Pharma - API & CRAMS outperforming NIFTY 500?
Pharma - API & CRAMS has outperformed NIFTY 500 by 20.8% over the last 52 weeks. Over 13 weeks the gap is a lead of 16.8%. 17 of 24 covered companies currently beat NIFTY on Mansfield relative strength, so leadership inside the sector is selective. Shilpa Medicare Ltd is the strongest against the sector itself at +59%.
+16.8%Sector vs NIFTY 500 · 13 weeks
+20.8%Sector vs NIFTY 500 · 52 weeks
17/24Stocks leading NIFTY 500
9/24Stocks leading sector
Sector metric: 35.6 as of 2026-08-09 · NARROWING · rising.
The central tension: the companies with the most scale are not necessarily the companies creating the most change.
Start with scale. Then earnings trajectory. Then business quality. Only after those three agree should price leadership carry much weight.
Bottom line
Pharma - API & CRAMS has outperformed NIFTY 500 by 20.8% over 52 weeks and 16.8% over 13 weeks. 17 of 24 covered companies beat NIFTY on Mansfield relative strength, while 9 of 24 beat the sector itself. Divis Laboratories Ltd leads with revenue of ₹11,230 crore, based on 24 of 24 comparable companies through Jun 2026.
Companies
24
complete canonical membership
Combined market value
₹6.9 L Cr
Divis Laboratories Ltd
Revenue growing
18/24
positive TTM year-on-year growth
Beating NIFTY 500
17/24
positive Mansfield relative strength
Comparing 5 of 24
04 · research priority, made explicit
Best Pharma - API & CRAMS Stocks in India (Aug 2026), Ranked by Data
4-Factor Sector Score
An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.
Growth & earnings · 35%Capital efficiency · 25%Valuation · 20%Relative strength · 20%
Neuland Laboratories Ltd has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 100% evidence confidence.
Blue Jet Healthcare Ltd looks inexpensive relative to peers or its own history, but its earnings trajectory has not yet earned the valuation signal.
How this score is built, and what the marks mean
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Top 10 Pharma - API & CRAMS Stocks in India
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Neuland Laboratories LtdNEULANDLAB | 82.7/100Sector-leading setup100% evidence | LEADER | 33.6/35 Revenue 78.3% · PAT 100% · OPM change 23 pp 100% evidence | 19.7/25 ROCE 26.5% · OPM 35% 100% evidence | 11.8/20 P/E 60.1× · PEG 1.05 100% evidence | 17.6/20 RS sector 19.2% · RS bench 44.6% · 1Y 78%12 of 12 weeks ahead 100% evidence |
| Exact sum: 33.6 + 19.7 + 11.8 + 17.6 = 82.7 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2IOL Chemicals & Pharmaceuticals LtdIOLCP | 73.8/100Favorable setup100% evidence | LEADER | 28.5/35 Revenue 18.5% · PAT 60% · OPM change 3 pp 100% evidence | 12.5/25 ROCE 11.3% · OPM 14% 100% evidence | 13.8/20 P/E 27.5× · PEG 0.66 100% evidence | 19.0/20 RS sector 33.1% · RS bench 59.6% · 1Y 78.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 28.5 + 12.5 + 13.8 + 19 = 73.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Gland Pharma LtdGLAND | 72.4/100Favorable setup100% evidence | LEADER | 26.4/35 Revenue 17.6% · PAT 46.4% · OPM change 3 pp 100% evidence | 13.9/25 ROCE 15.1% · OPM 27% 100% evidence | 13.7/20 P/E 42.8× · PEG 1.45 100% evidence | 18.4/20 RS sector 22.4% · RS bench 48.5% · 1Y 53.5%12 of 12 weeks ahead 100% evidence |
| Exact sum: 26.4 + 13.9 + 13.7 + 18.4 = 72.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Acutaas Chemicals Ltd543349 | 72.0/100Favorable setup82% evidence | LEADER | 31.9/35 Revenue 41% · PAT 100% · OPM change 9 pp 95% evidence | 20.1/25 ROCE 31.6% · OPM 34% 76% evidence | 7.9/20 P/E 68.6× · PEG — 50% evidence | 12.1/20 RS sector 17.1% · RS bench 41.3% · 1Y 152.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 31.9 + 20.1 + 7.9 + 12.1 = 72 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 5Laurus Labs LtdLAURUSLABS | 70.6/100Favorable setup93% evidence | LEADER | 32.2/35 Revenue 22.6% · PAT 100% · OPM change 8 pp 100% evidence | 18.2/25 ROCE 17.8% · OPM 32% 100% evidence | 5.3/20 P/E 88.3× · PEG 3.33 65% evidence | 14.9/20 RS sector 26.7% · RS bench 53.3% · 1Y 117.5%12 of 12 weeks ahead 100% evidence |
| Exact sum: 32.2 + 18.2 + 5.3 + 14.9 = 70.6 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 6Granules India LtdGRANULES | 64.5/100Mixed-positive evidence100% evidence | LEADER | 26.4/35 Revenue 24.8% · PAT 38.1% · OPM change 3 pp 100% evidence | 15.8/25 ROCE 15.5% · OPM 23% 100% evidence | 10.1/20 P/E 32.7× · PEG 1.27 100% evidence | 12.2/20 RS sector 7.7% · RS bench 30.8% · 1Y 95.3%12 of 12 weeks ahead 100% evidence |
| Exact sum: 26.4 + 15.8 + 10.1 + 12.2 = 64.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Divis Laboratories LtdDIVISLAB | 64.4/100Mixed-positive evidence100% evidence | BREAKING OUT | 26.5/35 Revenue 16.4% · PAT 26.8% · OPM change 11 pp 100% evidence | 19.1/25 ROCE 22% · OPM 41% 100% evidence | 3.8/20 P/E 75.5× · PEG 3.45 100% evidence | 15.0/20 RS sector 4.4% · RS bench 27.5% · 1Y 43.3%7 of 12 weeks ahead 100% evidence |
| Exact sum: 26.5 + 19.1 + 3.8 + 15 = 64.4 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 8Sai Life Sciences LtdSAILIFE | 63.5/100Mixed-positive evidence93% evidence | LEADER | 27.2/35 Revenue 17.6% · PAT 48% · OPM change 3 pp 100% evidence | 16.6/25 ROCE 19.6% · OPM 27% 100% evidence | 5.0/20 P/E 83.7× · PEG 3.46 65% evidence | 14.7/20 RS sector 16.1% · RS bench 41.1% · 1Y 75.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 27.2 + 16.6 + 5 + 14.7 = 63.5 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 9Shilpa Medicare LtdSHILPAMED | 63.3/100Mixed-positive evidence97% evidence | LEADER | 27.1/35 Revenue 28% · PAT 100% · OPM change 1 pp 95% evidence | 10.4/25 ROCE 11% · OPM 29% 95% evidence | 5.8/20 P/E 56.5× · PEG 6.86 100% evidence | 20.0/20 RS sector 59% · RS bench 90.7% · 1Y 97.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 27.1 + 10.4 + 5.8 + 20 = 63.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 10Anthem Biosciences LtdANTHEM | 54.7/100Mixed-positive evidence77% evidence | BREAKING OUT | 12.7/35 Revenue -2.1% · PAT 14.1% · OPM change 1 pp 100% evidence | 22.0/25 ROCE 30.4% · OPM 36% 100% evidence | 9.1/20 P/E 84.5× · PEG — 15% evidence | 10.9/20 RS sector -1.9% · RS bench 19.6% · 1Y 22%7 of 12 weeks ahead 70% evidence |
| Exact sum: 12.7 + 22 + 9.1 + 10.9 = 54.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Windlas Biotech LtdWINDLAS | 53.7/100Mixed-positive evidence77% evidence | TURNING | 16.7/35 Revenue 18.8% · PAT 9.8% · OPM change -2 pp 83% evidence | 14.5/25 ROCE 15.9% · OPM 11% 95% evidence | 11.6/20 P/E 29.5× · PEG — 50% evidence | 10.9/20 RS sector -1.8% · RS bench 10.3% · 1Y 3.3%3 of 10 weeks ahead 70% evidence |
| Exact sum: 16.7 + 14.5 + 11.6 + 10.9 = 53.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 12Morepen Laboratories LtdMOREPENLAB | 49.1/100Mixed-negative evidence94% evidence | BREAKING OUT | 20.3/35 Revenue 9.5% · PAT 51.6% · OPM change 8 pp 100% evidence | 8.2/25 ROCE 8.1% · OPM 14% 100% evidence | 10.4/20 P/E 39.3× · PEG 1.68 100% evidence | 10.2/20 RS sector -16.2% · RS bench 77.6% · 1Y 78.6%8 of 10 weeks ahead 70% evidence |
| Exact sum: 20.3 + 8.2 + 10.4 + 10.2 = 49.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13Supriya Lifescience LtdSUPRIYA | 47.7/100Mixed-negative evidence100% evidence | LEADER | 16.1/35 Revenue 28.2% · PAT 11.2% · OPM change -11 pp 100% evidence | 17.1/25 ROCE 25.1% · OPM 25% 100% evidence | 7.4/20 P/E 32.1× · PEG 3.11 100% evidence | 7.1/20 RS sector -14.3% · RS bench 4.2% · 1Y 20.4%12 of 12 weeks ahead 100% evidence |
| Exact sum: 16.1 + 17.1 + 7.4 + 7.1 = 47.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Blue Jet Healthcare LtdBLUEJET | 46.9/100Mixed-negative evidence94% evidence | BREAKING OUT | 5.6/35 Revenue -27.5% · PAT -34.6% · OPM change -1 pp 100% evidence | 21.1/25 ROCE 26.5% · OPM 33% 100% evidence | 14.0/20 P/E 47.1× · PEG 1.39 100% evidence | 6.2/20 RS sector -39.2% · RS bench 9.1% · 1Y -27.4%10 of 10 weeks ahead 70% evidence |
| Exact sum: 5.6 + 21.1 + 14 + 6.2 = 46.9 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 15SMS Pharmaceuticals LtdSMSPHARMA | 46.3/100Mixed-negative evidence100% evidence | ASLEEP | 19.1/35 Revenue 10.2% · PAT 41.7% · OPM change 0 pp 100% evidence | 11.3/25 ROCE 13.3% · OPM 20% 100% evidence | 10.9/20 P/E 33× · PEG 1.53 100% evidence | 5.0/20 RS sector -15.7% · RS bench 3.4% · 1Y 61.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.1 + 11.3 + 10.9 + 5 = 46.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Concord Biotech LtdCONCORDBIO | 38.5/100Mixed-negative evidence94% evidence | BREAKING OUT | 9.0/35 Revenue -6.7% · PAT -23.3% · OPM change 2 pp 100% evidence | 14.9/25 ROCE 17.1% · OPM 32% 100% evidence | 6.8/20 P/E 54.6× · PEG 5.67 100% evidence | 7.8/20 RS sector -23.6% · RS bench 7.4% · 1Y -9.2%8 of 10 weeks ahead 70% evidence |
| Exact sum: 9 + 14.9 + 6.8 + 7.8 = 38.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Piramal Pharma LtdPPLPHARMA | 34.7/100Adverse evidence71% evidence | LEADER | 13.0/35 Revenue 0.8% · PAT -80% · OPM change 3 pp 74% evidence | 1.4/25 ROCE 2.5% · OPM 9% 100% evidence | 10.0/20 P/E — · PEG — 0% evidence | 10.3/20 RS sector -5.3% · RS bench 15.6% · 1Y 8.7%10 of 12 weeks ahead 100% evidence |
| Exact sum: 13 + 1.4 + 10 + 10.3 = 34.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Jubilant Pharmova LtdJUBLPHARMA | 34.6/100Adverse evidence93% evidence | ASLEEP | 11.8/35 Revenue 16.3% · PAT -23% · OPM change -4 pp 100% evidence | 6.8/25 ROCE 9% · OPM 11% 100% evidence | 13.8/20 P/E 35.5× · PEG 1.17 65% evidence | 2.2/20 RS sector -30.5% · RS bench -14.8% · 1Y -21.5%7 of 12 weeks ahead 100% evidence |
| Exact sum: 11.8 + 6.8 + 13.8 + 2.2 = 34.6 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 19Hikal LtdHIKAL | 30.0/100Adverse evidence81% evidence | FADING | 11.3/35 Revenue -5.4% · PAT -80% · OPM change 2.6 pp 74% evidence | 4.3/25 ROCE 3.5% · OPM 9.2% 100% evidence | 6.6/20 P/E 63.4× · PEG — 50% evidence | 7.8/20 RS sector -19.1% · RS bench -1.1% · 1Y -25%7 of 12 weeks ahead 100% evidence |
| Exact sum: 11.3 + 4.3 + 6.6 + 7.8 = 30 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 20OneSource Specialty Pharma LtdONESOURCE | 27.3/100Adverse evidence71% evidence | ASLEEP | 11.3/35 Revenue 4.3% · PAT -80% · OPM change 0 pp 74% evidence | 3.3/25 ROCE 0.6% · OPM 27% 100% evidence | 10.0/20 P/E — · PEG — 0% evidence | 2.7/20 RS sector -24.1% · RS bench -7.3% · 1Y -17.6%5 of 12 weeks ahead 100% evidence |
| Exact sum: 11.3 + 3.3 + 10 + 2.7 = 27.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 21Syngene International LtdSYNGENE | 24.8/100Adverse evidence100% evidence | ASLEEP | 6.7/35 Revenue -3.4% · PAT -56.4% · OPM change -11.3 pp 100% evidence | 8.6/25 ROCE 10% · OPM 12.3% 100% evidence | 7.9/20 P/E 54.7× · PEG 7.87 100% evidence | 1.6/20 RS sector -38.7% · RS bench -24.5% · 1Y -38.7%1 of 12 weeks ahead 100% evidence |
| Exact sum: 6.7 + 8.6 + 7.9 + 1.6 = 24.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 22Cohance Lifesciences LtdCOHANCE | 23.1/100Adverse evidence82% evidence | ASLEEP | 3.7/35 Revenue -19.8% · PAT -80% · OPM change -19.7 pp 95% evidence | 7.2/25 ROCE 8.3% · OPM 0.3% 76% evidence | 6.5/20 P/E 157× · PEG — 50% evidence | 5.7/20 RS sector -32.5% · RS bench -18% · 1Y -52.8%9 of 12 weeks ahead 100% evidence |
| Exact sum: 3.7 + 7.2 + 6.5 + 5.7 = 23.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 23Solara Active Pharma Sciences LtdSOLARA | 22.7/100Adverse evidence83% evidence | ASLEEP | 7.9/35 Revenue 15.6% · PAT -80% · OPM change -2 pp 100% evidence | 3.8/25 ROCE 4.9% · OPM 16% 100% evidence | 8.5/20 P/E 573× · PEG — 15% evidence | 2.5/20 RS sector -24.7% · RS bench -8% · 1Y -12.8%8 of 12 weeks ahead 100% evidence |
| Exact sum: 7.9 + 3.8 + 8.5 + 2.5 = 22.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Dishman Carbogen Amcis LtdDCAL | 22.2/100Adverse evidence87% evidence | ASLEEP | 7.0/35 Revenue 0.2% · PAT -80% · OPM change -11 pp 100% evidence | 4.8/25 ROCE 3.1% · OPM 9% 100% evidence | 6.2/20 P/E 165× · PEG 2.65 65% evidence | 4.2/20 RS sector -31% · RS bench -13.2% · 1Y -19.3%6 of 10 weeks ahead 70% evidence |
| Exact sum: 7 + 4.8 + 6.2 + 4.2 = 22.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Showing 10 of 24 companies
05 · what price has already done
Market action
Acutaas Chemicals Ltd has the strongest one-year price move in Pharma - API & CRAMS at +152.6%. Shilpa Medicare Ltd leads on Mansfield relative strength against NIFTY at +90.7%. 17 of 24 covered companies are above zero on that measure. Every line covers 313 weekly closes through 2026-08-14.
Price and relative strength
Every company, the sector's own index and NIFTY 500 all start level on the left edge of the window, so only the distance between the lines counts — the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.
How far ahead of or behind NIFTY 500 each company has been running, measured against its own recent average of that comparison, so the flat line at zero IS NIFTY 500: above it the company is beating the market, below it the market is beating the company. It opens on one year.
The same measure taken against Pharma - API & CRAMS itself instead of the whole market, so the flat line at zero is the sector: above it the company is beating its own peers, which is the sharper test of the two. It opens on one year.
06 · the story behind the numbers
Pharma - API & CRAMS — the story behind the numbers
This is the written read behind the Pharma - API & CRAMS figures above — what is actually happening in the sector, in words, with the evidence each claim rests on. It is dated 22 Jul 2026. 4 themes are live here, 1 of them rated high severity.
The Pharma - API & CRAMS sector sample shows divergent operational metrics but aligned growth trajectories. Acutaas Chemicals Ltd reported Q4 FY26 revenue of Rs 433 crore, up 40.3% YoY. Granules India Ltd reported Q4 FY26 revenue of INR 14,706 Mn, up 23% YoY. Both constituents demonstrate revenue expansion exceeding 20% YoY.
How old this read is: This read comes from our Pharma - API & CRAMS sector brief dated 22 Jul 2026, so the words here and the numbers above them cover the same few weeks.
What is live in this sector right now
| Live theme | Severity | Evidence on file |
|---|---|---|
| Gagillapur facility FDA warning letter meeting January 2026; resolution delay caps margin expansion runway.Named for GRANULES | high | “Gagillapur facility — post-warning letter meeting with FDA January 2026; additional documentation submitted” Additional documentation submitted. |
| India pharma sector faces potential US tariff headwinds in FY27.Named for GRANULES | medium | “India pharma sector faces potential US tariff headwinds in FY27; Granules' US-heavy FD revenue mix makes it more exposed than peers with balanced geographies” |
| API price compression risk on commodity base (Paracetamol, Metformin).Named for GRANULES | medium | “Granules' historical vulnerability to API price compression is being structurally mitigated via product mix shift; however, the commodity API base (Paracetamol, Metformin) still contributes ~55% of FD revenue” Product mix shift toward Complex Generics. |
| Multi-currency exposure increasing with geographic diversification and acquisitions.Named for GRANULES | medium | FX management complexity rising with Senn integration. |
Sources: our Pharma - API & CRAMS sector brief, 22 Jul 2026 · company earnings-call transcripts.
07 · compare level, then change
Revenue Scale & Growth Durability
Divis Laboratories Ltd has the highest Revenue among the 24 Pharma - API & CRAMS companies compared here, at ₹11,230 crore. Piramal Pharma Ltd is next at ₹9,206 crore. Neuland Laboratories Ltd has the highest Revenue growth at 78.3%, so level and change sit with different companies. 24 of 24 companies report a comparable reading, the latest through Jun 2026.
What the numbers say: Divis Laboratories Ltd is the scale leader at ₹11,230 crore, 22% ahead of Piramal Pharma Ltd. Neuland Laboratories Ltd's growth is 78.3% from a ₹2,372 crore base, with 20 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.
LeaderDivis Laboratories Ltd · ₹11,230 crore
Gap22% versus #2 · Piramal Pharma Ltd
Persistence8/8 recent comparable periods
Coverage24/24 companies · 437 observations
Investor read: Divis Laboratories Ltd is the scale benchmark; Neuland Laboratories Ltd is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.
This conclusion weakens if: Divis Laboratories Ltd's growth falls below Neuland Laboratories Ltd's for two consecutive comparable reports while operating margin also compresses.
Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.
Revenuelargest
Revenue growthfastest growers
2Acutaas Chemicals Ltd 54334941%
Revenue · company comparison
24/24 level · 24/24 change
On every company-comparison chart on this page: solid lines show level, dotted lines show change when “Both” is selected, and a missing report breaks the line rather than being invented.
All-company data · latest reported quarter
In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | Revenue | Revenue growth | Reported |
|---|---|---|---|
| Divis Laboratories Ltd DIVISLAB | ₹3.1K Cr | 28% | Jun 2026 |
| Piramal Pharma Ltd PPLPHARMA | ₹2.3K Cr | 17% | Jun 2026 |
| Jubilant Pharmova Ltd JUBLPHARMA | ₹2.2K Cr | 17% | Jun 2026 |
| Laurus Labs Ltd LAURUSLABS | ₹2.0K Cr | 29% | Jun 2026 |
| Gland Pharma Ltd GLAND | ₹1.8K Cr | 20% | Jun 2026 |
| Granules India Ltd GRANULES | ₹1.5K Cr | 22% | Jun 2026 |
| IOL Chemicals & Pharmaceuticals Ltd IOLCP | ₹756 Cr | 37% | Jun 2026 |
| Syngene International Ltd SYNGENE | ₹736 Cr | -16% | Jun 2026 |
| Dishman Carbogen Amcis Ltd DCAL | ₹678 Cr | -4.2% | Jun 2026 |
| Neuland Laboratories Ltd NEULANDLAB | ₹642 Cr | 119% | Jun 2026 |
| Morepen Laboratories Ltd MOREPENLAB | ₹570 Cr | 34% | Jun 2026 |
| Sai Life Sciences Ltd SAILIFE | ₹554 Cr | 12% | Jun 2026 |
| Shilpa Medicare Ltd SHILPAMED | ₹466 Cr | 45% | Jun 2026 |
| OneSource Specialty Pharma Ltd ONESOURCE | ₹449 Cr | 37% | Jun 2026 |
| Cohance Lifesciences Ltd COHANCE | ₹422 Cr | -23% | Jun 2026 |
| Anthem Biosciences Ltd ANTHEM | ₹418 Cr | -23% | Jun 2026 |
| Hikal Ltd HIKAL | ₹403 Cr | 5.9% | Jun 2026 |
| Solara Active Pharma Sciences Ltd SOLARA | ₹382 Cr | 20% | Jun 2026 |
| Acutaas Chemicals Ltd 543349 | ₹330 Cr | 59% | Jun 2026 |
| Blue Jet Healthcare Ltd BLUEJET | ₹293 Cr | -17% | Jun 2026 |
| Concord Biotech Ltd CONCORDBIO | ₹257 Cr | 26% | Jun 2026 |
| Windlas Biotech Ltd WINDLAS⚠ unverified | ₹238 Cr | 17% | Mar 2026 |
| SMS Pharmaceuticals Ltd SMSPHARMA | ₹207 Cr | 5.6% | Jun 2026 |
| Supriya Lifescience Ltd SUPRIYA | ₹190 Cr | 31% | Jun 2026 |
Full 20-quarter history · every available company
Revenue · reported quarter history
Showing the 12 largest of 24 companies with a series here. The remaining 12 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Anthem Biosciences Ltd · ANTHEM
—
—
—
—
—
—
—
₹294 Cr
₹294 Cr
₹416 Cr
₹416 Cr
₹339 Cr
₹525 Cr
₹498 Cr
₹483 Cr
₹540 Cr
₹550 Cr
₹423 Cr
₹611 Cr
₹418 Cr
Cohance Lifesciences Ltd · COHANCE
—
—
—
—
—
₹354 Cr
₹369 Cr
₹348 Cr
₹231 Cr
₹220 Cr
₹253 Cr
₹488 Cr
₹604 Cr
₹676 Cr
₹840 Cr
₹549 Cr
₹556 Cr
₹545 Cr
₹619 Cr
₹422 Cr
Divis Laboratories Ltd · DIVISLAB
₹2.0K Cr
₹2.5K Cr
₹2.5K Cr
₹2.3K Cr
₹1.9K Cr
₹1.7K Cr
₹2.0K Cr
₹1.8K Cr
₹1.9K Cr
₹1.9K Cr
₹2.3K Cr
₹2.1K Cr
₹2.3K Cr
₹2.3K Cr
₹2.6K Cr
₹2.4K Cr
₹2.7K Cr
₹2.6K Cr
₹2.8K Cr
₹3.1K Cr
Gland Pharma Ltd · GLAND
₹1.1K Cr
₹1.1K Cr
₹1.1K Cr
₹857 Cr
₹1.0K Cr
₹938 Cr
₹785 Cr
₹1.2K Cr
₹1.4K Cr
₹1.5K Cr
₹1.5K Cr
₹1.4K Cr
₹1.4K Cr
₹1.4K Cr
₹1.4K Cr
₹1.5K Cr
₹1.5K Cr
₹1.7K Cr
₹1.7K Cr
₹1.8K Cr
Granules India Ltd · GRANULES
₹888 Cr
₹997 Cr
₹1.0K Cr
₹1.0K Cr
₹1.2K Cr
₹1.1K Cr
₹1.2K Cr
₹986 Cr
₹1.2K Cr
₹1.2K Cr
₹1.2K Cr
₹1.2K Cr
₹967 Cr
₹1.1K Cr
₹1.2K Cr
₹1.2K Cr
₹1.3K Cr
₹1.4K Cr
₹1.5K Cr
₹1.5K Cr
Laurus Labs Ltd · LAURUSLABS
₹1.2K Cr
₹1.0K Cr
₹1.4K Cr
₹1.5K Cr
₹1.6K Cr
₹1.5K Cr
₹1.4K Cr
₹1.2K Cr
₹1.2K Cr
₹1.2K Cr
₹1.4K Cr
₹1.2K Cr
₹1.2K Cr
₹1.4K Cr
₹1.7K Cr
₹1.6K Cr
₹1.7K Cr
₹1.8K Cr
₹1.8K Cr
₹2.0K Cr
Neuland Laboratories Ltd · NEULANDLAB
₹258 Cr
₹236 Cr
₹256 Cr
₹221 Cr
₹294 Cr
₹269 Cr
₹407 Cr
₹363 Cr
₹418 Cr
₹393 Cr
₹385 Cr
₹440 Cr
₹311 Cr
₹398 Cr
₹328 Cr
₹293 Cr
₹514 Cr
₹440 Cr
₹776 Cr
₹642 Cr
OneSource Specialty Pharma Ltd · ONESOURCE
—
—
—
—
—
—
—
₹9 Cr
₹34 Cr
₹56 Cr
₹73 Cr
₹292 Cr
₹334 Cr
₹393 Cr
₹426 Cr
₹327 Cr
₹376 Cr
₹290 Cr
₹428 Cr
₹449 Cr
Piramal Pharma Ltd · PPLPHARMA
₹1.6K Cr
₹1.5K Cr
₹2.3K Cr
₹1.5K Cr
₹1.8K Cr
₹1.7K Cr
₹2.2K Cr
₹1.7K Cr
₹1.9K Cr
₹2.0K Cr
₹2.6K Cr
₹2.0K Cr
₹2.2K Cr
₹2.2K Cr
₹2.8K Cr
₹1.9K Cr
₹2.0K Cr
₹2.1K Cr
₹2.8K Cr
₹2.3K Cr
Sai Life Sciences Ltd · SAILIFE
—
—
—
—
—
—
—
₹321 Cr
₹321 Cr
₹384 Cr
₹439 Cr
₹280 Cr
₹396 Cr
₹440 Cr
₹580 Cr
₹496 Cr
₹537 Cr
₹556 Cr
₹602 Cr
₹554 Cr
Syngene International Ltd · SYNGENE
₹610 Cr
₹641 Cr
₹758 Cr
₹645 Cr
₹768 Cr
₹786 Cr
₹994 Cr
₹808 Cr
₹910 Cr
₹854 Cr
₹917 Cr
₹790 Cr
₹891 Cr
₹944 Cr
₹1.0K Cr
₹875 Cr
₹911 Cr
₹917 Cr
₹1.0K Cr
₹736 Cr
Revenue growth · reported quarter history
Showing the 12 largest of 24 companies with a series here. The remaining 12 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Acutaas Chemicals Ltd · 543349
—
—
—
—
—
—
—
—
—
9.2%
21%
15%
44%
66%
37%
17%
24%
43%
41%
59%
Anthem Biosciences Ltd · ANTHEM
—
—
—
—
—
—
—
—
—
—
—
15%
79%
20%
16%
59%
4.8%
-15%
27%
-23%
Cohance Lifesciences Ltd · COHANCE
—
—
—
—
—
—
—
—
—
-38%
-32%
40%
161%
207%
232%
13%
-8.0%
-19%
-26%
-23%
Divis Laboratories Ltd · DIVISLAB
—
—
—
15%
-6.7%
-31%
-23%
-21%
2.9%
8.6%
18%
19%
22%
25%
12%
14%
16%
12%
9.5%
28%
Gland Pharma Ltd · GLAND
—
—
—
-26%
-3.3%
-12%
-29%
41%
32%
65%
96%
16%
2.4%
-10%
-7.3%
7.4%
5.8%
22%
22%
20%
Granules India Ltd · GRANULES
—
—
—
—
30%
15%
16%
-3.3%
3.3%
0.9%
-1.7%
20%
-19%
-1.6%
1.8%
2.5%
34%
22%
23%
22%
Laurus Labs Ltd · LAURUSLABS
—
—
—
20%
31%
50%
-3.1%
-23%
-22%
-23%
4.3%
1.1%
0.0%
18%
19%
31%
35%
26%
5.4%
29%
Neuland Laboratories Ltd · NEULANDLAB
—
—
—
10.0%
14%
14%
59%
64%
42%
46%
-5.4%
21%
-26%
1.3%
-15%
-33%
65%
11%
137%
119%
OneSource Specialty Pharma Ltd · ONESOURCE
—
—
—
—
—
—
—
—
—
—
—
3,144%
882%
602%
484%
12%
13%
-26%
0.5%
37%
Piramal Pharma Ltd · PPLPHARMA
—
—
—
1.3%
11%
14%
-6.2%
18%
8.2%
14%
18%
12%
17%
13%
7.9%
-0.9%
-8.8%
-2.9%
-0.1%
17%
Sai Life Sciences Ltd · SAILIFE
—
—
—
—
—
—
—
—
—
—
—
-13%
23%
15%
32%
77%
36%
26%
3.8%
12%
Syngene International Ltd · SYNGENE
—
—
—
8.4%
26%
23%
31%
25%
19%
8.6%
-7.8%
-2.3%
-2.1%
11%
11%
11%
2.2%
-2.8%
1.8%
-16%
08 · compare level, then change
Operating Economics & Margin Trend
Divis Laboratories Ltd has the highest OPM among the 24 Pharma - API & CRAMS companies compared here, at 41%. Anthem Biosciences Ltd is next at 36%. Neuland Laboratories Ltd has the highest Margin change at +23 percentage points, so level and change sit with different companies. 24 of 24 companies report a comparable reading, the latest through Jun 2026.
What the numbers say: Divis Laboratories Ltd leads opm at 41%; Neuland Laboratories Ltd leads margin change at +23 percentage points.
LeaderDivis Laboratories Ltd · 41%
Gap13.9% versus #2 · Anthem Biosciences Ltd
Persistence7/8 recent comparable periods
Coverage24/24 companies · 452 observations
Investor read: Divis Laboratories Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current margin change signal.
Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.
OPMhighest
4Acutaas Chemicals Ltd 54334934%
Margin changefastest expanders
3Acutaas Chemicals Ltd 543349+9.0 pp
Operating margin · company comparison
24/24 level · 24/24 change
All-company data · latest reported quarter
| Company | OPM | Margin change | Reported |
|---|---|---|---|
| Divis Laboratories Ltd DIVISLAB | 41% | +11.0 pp | Jun 2026 |
| Anthem Biosciences Ltd ANTHEM | 36% | +1.0 pp | Jun 2026 |
| Neuland Laboratories Ltd NEULANDLAB | 35% | +23.0 pp | Jun 2026 |
| Acutaas Chemicals Ltd 543349 | 34% | +9.0 pp | Jun 2026 |
| Blue Jet Healthcare Ltd BLUEJET | 33% | −1.0 pp | Jun 2026 |
| Laurus Labs Ltd LAURUSLABS | 32% | +8.0 pp | Jun 2026 |
| Concord Biotech Ltd CONCORDBIO | 32% | +2.0 pp | Jun 2026 |
| Shilpa Medicare Ltd SHILPAMED | 29% | +1.0 pp | Jun 2026 |
| Gland Pharma Ltd GLAND | 27% | +3.0 pp | Jun 2026 |
| Sai Life Sciences Ltd SAILIFE | 27% | +3.0 pp | Jun 2026 |
| OneSource Specialty Pharma Ltd ONESOURCE | 27% | 0.0 pp | Jun 2026 |
| Supriya Lifescience Ltd SUPRIYA | 25% | −11.0 pp | Jun 2026 |
| Granules India Ltd GRANULES | 23% | +3.0 pp | Jun 2026 |
| SMS Pharmaceuticals Ltd SMSPHARMA | 20% | 0.0 pp | Jun 2026 |
| Solara Active Pharma Sciences Ltd SOLARA | 16% | −2.0 pp | Jun 2026 |
| IOL Chemicals & Pharmaceuticals Ltd IOLCP | 14% | +3.0 pp | Jun 2026 |
| Morepen Laboratories Ltd MOREPENLAB | 14% | +8.0 pp | Jun 2026 |
| Syngene International Ltd SYNGENE | 12% | −11.3 pp | Jun 2026 |
| Jubilant Pharmova Ltd JUBLPHARMA | 11% | −4.0 pp | Jun 2026 |
| Windlas Biotech Ltd WINDLAS⚠ unverified | 11% | −2.0 pp | Mar 2026 |
| Hikal Ltd HIKAL | 9.2% | +2.6 pp | Jun 2026 |
| Piramal Pharma Ltd PPLPHARMA | 9.0% | +3.0 pp | Jun 2026 |
| Dishman Carbogen Amcis Ltd DCAL | 9.0% | −11.0 pp | Jun 2026 |
| Cohance Lifesciences Ltd COHANCE | 0.3% | −19.7 pp | Jun 2026 |
Full 20-quarter history · every available company
OPM · reported quarter history
Showing the 12 largest of 24 companies with a series here. The remaining 12 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Acutaas Chemicals Ltd · 543349
22%
21%
18%
17%
19%
20%
22%
22%
14%
16%
19%
17%
20%
25%
28%
25%
31%
38%
42%
34%
Anthem Biosciences Ltd · ANTHEM
—
—
—
—
—
—
—
30%
30%
30%
30%
36%
37%
32%
40%
35%
40%
37%
44%
36%
Cohance Lifesciences Ltd · COHANCE
40%
48%
43%
45%
36%
41%
47%
48%
42%
30%
29%
26%
34%
35%
27%
20%
22%
18%
16%
0.3%
Divis Laboratories Ltd · DIVISLAB
41%
44%
44%
38%
33%
24%
25%
28%
25%
26%
32%
29%
31%
32%
34%
30%
33%
34%
33%
41%
Gland Pharma Ltd · GLAND
35%
33%
32%
32%
28%
31%
21%
24%
24%
23%
23%
19%
21%
26%
24%
24%
21%
26%
29%
27%
Granules India Ltd · GRANULES
17%
17%
19%
21%
21%
20%
19%
14%
18%
22%
22%
22%
21%
20%
21%
20%
21%
22%
24%
23%
Laurus Labs Ltd · LAURUSLABS
29%
28%
28%
30%
28%
26%
21%
14%
15%
15%
17%
14%
15%
20%
24%
24%
24%
27%
28%
32%
Neuland Laboratories Ltd · NEULANDLAB
17%
14%
15%
13%
24%
20%
29%
27%
33%
31%
28%
28%
20%
22%
16%
12%
30%
18%
40%
35%
OneSource Specialty Pharma Ltd · ONESOURCE
—
—
—
—
—
—
—
-632%
-114%
-19%
-3.8%
22%
23%
36%
43%
27%
28%
6.0%
21%
27%
Piramal Pharma Ltd · PPLPHARMA
12%
15%
19%
1.2%
10%
5.0%
16%
8.0%
14%
14%
21%
10%
15%
15%
20%
6.0%
8.0%
9.0%
17%
9.0%
Sai Life Sciences Ltd · SAILIFE
—
—
—
—
—
—
—
2.1%
10%
25%
28%
9.0%
26%
27%
27%
24%
27%
34%
29%
27%
Syngene International Ltd · SYNGENE
29%
32%
33%
27%
28%
29%
32%
26%
28%
27%
35%
22%
27%
30%
34%
24%
22%
23%
29%
12%
Margin change · reported quarter history
Showing the 12 largest of 24 companies with a series here. The remaining 12 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Acutaas Chemicals Ltd · 543349
−1.6 pp
−2.4 pp
−7.1 pp
−2.0 pp
−3.2 pp
−1.2 pp
+4.0 pp
+4.5 pp
−5.1 pp
−4.0 pp
−3.0 pp
−5.0 pp
+6.0 pp
+9.0 pp
+9.0 pp
+8.0 pp
+11.0 pp
+13.0 pp
+14.0 pp
+9.0 pp
Anthem Biosciences Ltd · ANTHEM
—
—
—
—
—
—
—
—
—
—
—
+5.6 pp
+6.6 pp
+2.5 pp
+10.5 pp
−1.0 pp
+3.0 pp
+5.0 pp
+4.0 pp
+1.0 pp
Cohance Lifesciences Ltd · COHANCE
−0.8 pp
−2.5 pp
+7.0 pp
+1.1 pp
−4.6 pp
−6.5 pp
+3.4 pp
+3.5 pp
+6.1 pp
−11.0 pp
−17.5 pp
−22.0 pp
−8.0 pp
+5.0 pp
−2.0 pp
−6.0 pp
−12.0 pp
−17.0 pp
−11.0 pp
−19.7 pp
Divis Laboratories Ltd · DIVISLAB
−1.2 pp
+3.4 pp
+3.8 pp
−5.8 pp
−7.7 pp
−20.0 pp
−18.9 pp
−9.7 pp
−8.5 pp
+2.0 pp
+7.0 pp
+1.0 pp
+6.0 pp
+6.0 pp
+2.0 pp
+1.0 pp
+2.0 pp
+2.0 pp
−1.0 pp
+11.0 pp
Gland Pharma Ltd · GLAND
−0.9 pp
+2.1 pp
−5.3 pp
−6.3 pp
−6.4 pp
−1.8 pp
−10.6 pp
−7.5 pp
−4.4 pp
−8.0 pp
+2.0 pp
−5.0 pp
−3.0 pp
+3.0 pp
+1.0 pp
+5.0 pp
0.0 pp
0.0 pp
+5.0 pp
+3.0 pp
Granules India Ltd · GRANULES
−12.9 pp
−7.6 pp
−6.6 pp
−3.0 pp
+4.1 pp
+2.6 pp
+0.3 pp
−6.7 pp
−3.1 pp
+2.0 pp
+3.0 pp
+8.0 pp
+3.0 pp
−2.0 pp
−1.0 pp
−2.0 pp
0.0 pp
+2.0 pp
+3.0 pp
+3.0 pp
Laurus Labs Ltd · LAURUSLABS
−4.2 pp
−5.4 pp
−5.6 pp
−1.4 pp
−0.2 pp
−1.7 pp
−6.8 pp
−15.5 pp
−13.5 pp
−11.0 pp
−4.0 pp
0.0 pp
0.0 pp
+5.0 pp
+7.0 pp
+10.0 pp
+9.0 pp
+7.0 pp
+4.0 pp
+8.0 pp
Neuland Laboratories Ltd · NEULANDLAB
−0.3 pp
−5.3 pp
+4.8 pp
+0.2 pp
+7.0 pp
+6.3 pp
+13.8 pp
+14.1 pp
+9.4 pp
+11.0 pp
−1.0 pp
+1.0 pp
−13.0 pp
−9.0 pp
−12.0 pp
−16.0 pp
+10.0 pp
−4.0 pp
+24.0 pp
+23.0 pp
OneSource Specialty Pharma Ltd · ONESOURCE
—
—
—
—
—
—
—
—
—
—
—
+653.5 pp
+137.0 pp
+55.0 pp
+46.8 pp
+5.0 pp
+5.0 pp
−30.0 pp
−22.0 pp
0.0 pp
Piramal Pharma Ltd · PPLPHARMA
—
—
—
−2.0 pp
−2.4 pp
−9.7 pp
−2.4 pp
+6.9 pp
+4.0 pp
+9.0 pp
+4.8 pp
+2.0 pp
+1.0 pp
+1.0 pp
−1.0 pp
−4.0 pp
−7.0 pp
−6.0 pp
−3.0 pp
+3.0 pp
Sai Life Sciences Ltd · SAILIFE
—
—
—
—
—
—
—
—
—
—
—
+6.9 pp
+16.0 pp
+2.0 pp
−1.0 pp
+15.0 pp
+1.0 pp
+7.0 pp
+2.0 pp
+3.0 pp
Syngene International Ltd · SYNGENE
−0.9 pp
+1.6 pp
+0.3 pp
−0.9 pp
−0.9 pp
−2.7 pp
−1.0 pp
−0.6 pp
−0.3 pp
−1.9 pp
+2.6 pp
−4.7 pp
−0.5 pp
+2.9 pp
−0.8 pp
+2.1 pp
−5.6 pp
−7.2 pp
−4.5 pp
−11.3 pp
09 · compare level, then change
Profit Scale & Acceleration
Divis Laboratories Ltd has the highest Net profit among the 24 Pharma - API & CRAMS companies compared here, at ₹2,925 crore. Gland Pharma Ltd is next at ₹1,129 crore. Acutaas Chemicals Ltd has the highest Profit growth at the 100% top of the scoring scale, so level and change sit with different companies.
What the numbers say: Divis Laboratories Ltd leads with ₹2,925 crore of TTM profit, 159.1% above Gland Pharma Ltd. Acutaas Chemicals Ltd shows ≥100% on the scoring scale (103.7% uncapped) growth from a ₹387 crore profit base. Compare the size of the base and persistence before ranking acceleration above profit scale.
LeaderDivis Laboratories Ltd · ₹2,925 crore
Gap159.1% versus #2 · Gland Pharma Ltd
Persistence7/8 recent comparable periods
Coverage24/24 companies · 437 observations
Investor read: Divis Laboratories Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.
Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.
Net profitlargest
Profit growthfastest growers
1Acutaas Chemicals Ltd 543349100%
Net profit · company comparison
24/24 level · 21/24 change
All-company data · latest reported quarter
| Company | Net profit | Profit growth | Reported |
|---|---|---|---|
| Divis Laboratories Ltd DIVISLAB | ₹902 Cr | 66% | Jun 2026 |
| Laurus Labs Ltd LAURUSLABS | ₹362 Cr | 123% | Jun 2026 |
| Gland Pharma Ltd GLAND | ₹317 Cr | 47% | Jun 2026 |
| Granules India Ltd GRANULES | ₹180 Cr | 59% | Jun 2026 |
| Neuland Laboratories Ltd NEULANDLAB | ₹148 Cr | 957% | Jun 2026 |
| Anthem Biosciences Ltd ANTHEM | ₹120 Cr | -12% | Jun 2026 |
| Shilpa Medicare Ltd SHILPAMED | ₹101 Cr | 115% | Jun 2026 |
| Blue Jet Healthcare Ltd BLUEJET | ₹78 Cr | -14% | Jun 2026 |
| Acutaas Chemicals Ltd 543349 | ₹75 Cr | 70% | Jun 2026 |
| Sai Life Sciences Ltd SAILIFE | ₹73 Cr | 22% | Jun 2026 |
| IOL Chemicals & Pharmaceuticals Ltd IOLCP | ₹64 Cr | 88% | Jun 2026 |
| Concord Biotech Ltd CONCORDBIO | ₹58 Cr | 32% | Jun 2026 |
| Jubilant Pharmova Ltd JUBLPHARMA | ₹56 Cr | -45% | Jun 2026 |
| Morepen Laboratories Ltd MOREPENLAB | ₹56 Cr | 409% | Jun 2026 |
| OneSource Specialty Pharma Ltd ONESOURCE | ₹25 Cr | -95% | Jun 2026 |
| Supriya Lifescience Ltd SUPRIYA | ₹24 Cr | -31% | Jun 2026 |
| SMS Pharmaceuticals Ltd SMSPHARMA | ₹21 Cr | 5.0% | Jun 2026 |
| Solara Active Pharma Sciences Ltd SOLARA | ₹16 Cr | 45% | Jun 2026 |
| Windlas Biotech Ltd WINDLAS⚠ unverified | ₹16 Cr | 0.0% | Mar 2026 |
| Hikal Ltd HIKAL | ₹-7 Cr | -71% | Jun 2026 |
| Syngene International Ltd SYNGENE | ₹-9 Cr | -110% | Jun 2026 |
| Cohance Lifesciences Ltd COHANCE | ₹-45 Cr | -198% | Jun 2026 |
| Dishman Carbogen Amcis Ltd DCAL | ₹-58 Cr | -352% | Jun 2026 |
| Piramal Pharma Ltd PPLPHARMA | ₹-69 Cr | -106% | Jun 2026 |
Full 20-quarter history · every available company
Net profit · reported quarter history
Showing the 12 largest of 24 companies with a series here. The remaining 12 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Acutaas Chemicals Ltd · 543349
—
—
—
—
—
₹22 Cr
₹27 Cr
₹22 Cr
₹-17 Cr
₹18 Cr
₹26 Cr
₹15 Cr
₹38 Cr
₹45 Cr
₹63 Cr
₹44 Cr
₹72 Cr
₹106 Cr
₹134 Cr
₹75 Cr
Anthem Biosciences Ltd · ANTHEM
—
—
—
—
—
—
—
₹79 Cr
₹79 Cr
₹105 Cr
₹105 Cr
₹82 Cr
₹162 Cr
₹124 Cr
₹83 Cr
₹136 Cr
₹173 Cr
₹93 Cr
₹190 Cr
₹120 Cr
Cohance Lifesciences Ltd · COHANCE
—
—
—
—
—
₹108 Cr
₹124 Cr
₹121 Cr
₹80 Cr
₹47 Cr
₹53 Cr
₹75 Cr
₹138 Cr
₹153 Cr
₹117 Cr
₹46 Cr
₹66 Cr
₹29 Cr
₹8 Cr
₹-45 Cr
Divis Laboratories Ltd · DIVISLAB
₹606 Cr
₹902 Cr
₹895 Cr
₹702 Cr
₹494 Cr
₹306 Cr
₹321 Cr
₹356 Cr
₹348 Cr
₹358 Cr
₹538 Cr
₹430 Cr
₹510 Cr
₹589 Cr
₹662 Cr
₹545 Cr
₹689 Cr
₹583 Cr
₹751 Cr
₹902 Cr
Gland Pharma Ltd · GLAND
₹302 Cr
₹273 Cr
₹286 Cr
₹229 Cr
₹241 Cr
₹232 Cr
₹79 Cr
₹194 Cr
₹194 Cr
₹192 Cr
₹192 Cr
₹144 Cr
₹164 Cr
₹205 Cr
₹187 Cr
₹215 Cr
₹184 Cr
₹261 Cr
₹367 Cr
₹317 Cr
Granules India Ltd · GRANULES
₹81 Cr
₹101 Cr
₹111 Cr
₹128 Cr
₹145 Cr
₹124 Cr
₹120 Cr
₹48 Cr
₹102 Cr
₹126 Cr
₹130 Cr
₹135 Cr
₹97 Cr
₹118 Cr
₹152 Cr
₹113 Cr
₹131 Cr
₹150 Cr
₹202 Cr
₹180 Cr
Laurus Labs Ltd · LAURUSLABS
₹202 Cr
₹154 Cr
₹231 Cr
₹251 Cr
₹233 Cr
₹203 Cr
₹105 Cr
₹27 Cr
₹37 Cr
₹23 Cr
₹75 Cr
₹13 Cr
₹20 Cr
₹93 Cr
₹233 Cr
₹162 Cr
₹194 Cr
₹252 Cr
₹282 Cr
₹362 Cr
Neuland Laboratories Ltd · NEULANDLAB
₹20 Cr
₹13 Cr
₹22 Cr
₹10 Cr
₹38 Cr
₹31 Cr
₹85 Cr
₹62 Cr
₹89 Cr
₹81 Cr
₹68 Cr
₹98 Cr
₹33 Cr
₹102 Cr
₹28 Cr
₹14 Cr
₹97 Cr
₹41 Cr
₹213 Cr
₹148 Cr
OneSource Specialty Pharma Ltd · ONESOURCE
—
—
—
—
—
—
—
₹-107 Cr
₹-114 Cr
₹-130 Cr
₹-40 Cr
₹-6 Cr
₹-42 Cr
₹-69 Cr
₹98 Cr
₹0 Cr
₹10 Cr
₹-89 Cr
₹5 Cr
₹25 Cr
Piramal Pharma Ltd · PPLPHARMA
₹37 Cr
₹163 Cr
₹204 Cr
₹-109 Cr
₹-37 Cr
₹-90 Cr
₹50 Cr
₹-99 Cr
₹5 Cr
₹10 Cr
₹101 Cr
₹-89 Cr
₹23 Cr
₹4 Cr
₹154 Cr
₹-82 Cr
₹-99 Cr
₹-136 Cr
₹-9 Cr
₹-69 Cr
Sai Life Sciences Ltd · SAILIFE
—
—
—
—
—
—
—
₹-6 Cr
₹-6 Cr
₹40 Cr
₹56 Cr
₹-14 Cr
₹42 Cr
₹54 Cr
₹88 Cr
₹60 Cr
₹84 Cr
₹100 Cr
₹104 Cr
₹73 Cr
Syngene International Ltd · SYNGENE
₹67 Cr
₹104 Cr
₹148 Cr
₹74 Cr
₹102 Cr
₹110 Cr
₹179 Cr
₹93 Cr
₹117 Cr
₹112 Cr
₹189 Cr
₹76 Cr
₹106 Cr
₹131 Cr
₹183 Cr
₹87 Cr
₹67 Cr
₹15 Cr
₹148 Cr
₹-9 Cr
Profit growth · reported quarter history
Showing the 12 largest of 24 companies with a series here. The remaining 12 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Acutaas Chemicals Ltd · 543349
—
—
—
—
—
—
—
—
—
-18%
-3.7%
-32%
—
150%
142%
193%
89%
136%
113%
70%
Anthem Biosciences Ltd · ANTHEM
—
—
—
—
—
—
—
—
—
—
—
3.8%
105%
18%
-21%
66%
6.8%
-25%
129%
-12%
Cohance Lifesciences Ltd · COHANCE
—
—
—
—
—
—
—
—
—
-56%
-57%
-38%
73%
226%
121%
-39%
-52%
-81%
-93%
-198%
Divis Laboratories Ltd · DIVISLAB
—
—
—
26%
-18%
-66%
-64%
-49%
-30%
17%
68%
21%
47%
65%
23%
27%
35%
-1.0%
13%
66%
Gland Pharma Ltd · GLAND
—
—
—
-35%
-20%
-15%
-72%
-15%
-20%
-17%
143%
-26%
-15%
6.8%
-2.6%
49%
12%
27%
96%
47%
Granules India Ltd · GRANULES
—
—
—
—
79%
23%
8.1%
-63%
-30%
1.6%
8.3%
181%
-4.9%
-6.4%
17%
-16%
35%
27%
33%
59%
Laurus Labs Ltd · LAURUSLABS
—
—
—
4.2%
15%
32%
-55%
-89%
-84%
-89%
-29%
-52%
-46%
304%
211%
1,146%
870%
171%
21%
123%
Neuland Laboratories Ltd · NEULANDLAB
—
—
—
11%
90%
138%
286%
520%
134%
161%
-20%
58%
-63%
26%
-59%
-86%
194%
-60%
661%
957%
OneSource Specialty Pharma Ltd · ONESOURCE
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
-95%
—
Piramal Pharma Ltd · PPLPHARMA
—
—
—
-2,825%
-200%
-155%
-75%
—
—
—
102%
—
360%
-60%
52%
—
-530%
-3,500%
-106%
—
Sai Life Sciences Ltd · SAILIFE
—
—
—
—
—
—
—
—
—
—
—
—
—
35%
57%
—
100%
85%
18%
22%
Syngene International Ltd · SYNGENE
—
—
—
-3.9%
52%
5.8%
21%
26%
14%
1.4%
5.4%
-19%
-8.9%
18%
-2.8%
15%
-37%
-89%
-19%
-110%
10 · compare level, then change
Return On Capital Employed
Acutaas Chemicals Ltd has the highest ROCE among the 24 Pharma - API & CRAMS companies compared here, at 31.6%. Anthem Biosciences Ltd is next at 30.4%. The same company also holds the highest ROCE change, at +12 percentage points. 24 of 24 companies report a comparable reading, the latest through Jun 2026.
What the numbers say: Acutaas Chemicals Ltd leads ROCE at 31.6%, 1.2 percentage points above Anthem Biosciences Ltd. Acutaas Chemicals Ltd has the strongest latest improvement at +12 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.
LeaderAcutaas Chemicals Ltd · 31.6%
Gap3.9% versus #2 · Anthem Biosciences Ltd
PersistenceNot enough history
Coverage24/24 companies · 309 observations
Investor read: Acutaas Chemicals Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current roce change signal.
ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.
ROCEhighest
1Acutaas Chemicals Ltd 54334932%
ROCE changefastest improvers
1Acutaas Chemicals Ltd 543349+12.0 pp
Return on capital · company comparison
24/24 level · 24/24 change
Withheld from this chart: Cohance Lifesciences Ltd (COHANCE) — its two data sources disagree by up to 129% on reported income across 14 comparable periods, so its derived ratios are withheld. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
All-company data · latest reported quarter
| Company | ROCE | ROCE change | Reported |
|---|---|---|---|
| Anthem Biosciences Ltd ANTHEM | 28% | −4.1 pp | Jun 2026 |
| Laurus Labs Ltd LAURUSLABS | 25% | +8.9 pp | Jun 2026 |
| Divis Laboratories Ltd DIVISLAB | 23% | +2.5 pp | Jun 2026 |
| Neuland Laboratories Ltd NEULANDLAB | 22% | +6.5 pp | Jun 2026 |
| Supriya Lifescience Ltd SUPRIYA | 22% | −1.8 pp | Jun 2026 |
| Granules India Ltd GRANULES | 20% | +1.2 pp | Jun 2026 |
| Blue Jet Healthcare Ltd BLUEJET | 19% | −11.9 pp | Jun 2026 |
| Sai Life Sciences Ltd SAILIFE | 17% | +5.5 pp | Jun 2026 |
| Concord Biotech Ltd CONCORDBIO | 15% | −10.3 pp | Jun 2026 |
| SMS Pharmaceuticals Ltd SMSPHARMA | 13% | +0.3 pp | Jun 2026 |
| Windlas Biotech Ltd WINDLAS⚠ unverified | 13% | −0.4 pp | Mar 2026 |
| Gland Pharma Ltd GLAND | 11% | +2.1 pp | Jun 2026 |
| Shilpa Medicare Ltd SHILPAMED | 11% | +3.6 pp | Jun 2026 |
| IOL Chemicals & Pharmaceuticals Ltd IOLCP | 10% | +2.6 pp | Jun 2026 |
| Syngene International Ltd SYNGENE | 9.6% | −1.8 pp | Jun 2026 |
| Jubilant Pharmova Ltd JUBLPHARMA | 6.3% | −1.3 pp | Jun 2026 |
| Morepen Laboratories Ltd MOREPENLAB | 6.2% | −5.2 pp | Jun 2026 |
| Solara Active Pharma Sciences Ltd SOLARA | 6.1% | −2.3 pp | Jun 2026 |
| Hikal Ltd HIKAL | 3.4% | −7.8 pp | Jun 2026 |
| Dishman Carbogen Amcis Ltd DCAL | 2.4% | 0.0 pp | Jun 2026 |
| Piramal Pharma Ltd PPLPHARMA | 0.7% | −4.6 pp | Jun 2026 |
| OneSource Specialty Pharma Ltd ONESOURCE | 0.4% | −2.5 pp | Jun 2026 |
Full 20-quarter history · every available company
ROCE · reported quarter history
Showing the 12 largest of 22 companies with a series here. The remaining 10 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Anthem Biosciences Ltd · ANTHEM
—
—
—
—
—
—
—
—
—
15%
21%
—
23%
—
24%
32%
23%
28%
23%
28%
Concord Biotech Ltd · CONCORDBIO
—
—
—
—
—
—
23%
—
28%
30%
25%
29%
26%
29%
25%
28%
21%
24%
15%
—
Divis Laboratories Ltd · DIVISLAB
27%
—
29%
—
27%
—
15%
—
12%
15%
13%
17%
15%
20%
17%
21%
17%
22%
17%
23%
Gland Pharma Ltd · GLAND
20%
—
19%
—
15%
—
11%
—
9.8%
12%
11%
13%
9.4%
12%
9.0%
13%
9.6%
13%
11%
—
Granules India Ltd · GRANULES
23%
—
20%
—
23%
—
24%
—
19%
21%
19%
24%
20%
22%
17%
19%
17%
20%
16%
20%
Laurus Labs Ltd · LAURUSLABS
37%
—
27%
—
28%
—
25%
—
14%
9.4%
7.5%
7.7%
6.8%
9.4%
11%
16%
17%
23%
19%
25%
Neuland Laboratories Ltd · NEULANDLAB
9.9%
—
9.4%
—
12%
—
20%
—
29%
38%
29%
36%
23%
29%
16%
16%
14%
15%
22%
—
OneSource Specialty Pharma Ltd · ONESOURCE
—
—
—
—
—
—
—
—
—
—
-15%
-32%
-0.8%
-0.6%
2.9%
3.5%
3.7%
2.0%
0.4%
—
Piramal Pharma Ltd · PPLPHARMA
—
—
6.1%
—
3.6%
1.3%
-1.1%
—
0.1%
4.5%
4.2%
6.3%
5.9%
7.6%
5.3%
6.8%
2.7%
3.8%
0.7%
—
Sai Life Sciences Ltd · SAILIFE
—
—
—
—
—
—
—
—
—
—
12%
—
14%
17%
11%
20%
16%
23%
17%
—
Shilpa Medicare Ltd · SHILPAMED
2.9%
—
5.3%
—
2.8%
—
-0.3%
—
2.6%
4.8%
5.4%
7.8%
6.9%
8.9%
7.4%
8.5%
8.6%
9.4%
11%
—
Syngene International Ltd · SYNGENE
11%
—
10%
—
12%
—
13%
—
15%
15%
13%
13%
11%
14%
11%
14%
12%
9.6%
9.6%
—
ROCE change · reported quarter history
Showing the 12 largest of 22 companies with a series here. The remaining 10 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Anthem Biosciences Ltd · ANTHEM
—
—
—
—
—
—
—
—
—
—
—
—
—
—
+3.1 pp
—
+0.9 pp
—
−0.9 pp
−4.1 pp
Concord Biotech Ltd · CONCORDBIO
—
—
—
—
—
—
—
—
—
—
+2.1 pp
—
−2.6 pp
−0.4 pp
+0.2 pp
−1.6 pp
−4.9 pp
−5.5 pp
−10.3 pp
—
Divis Laboratories Ltd · DIVISLAB
—
—
—
—
−0.6 pp
—
−14.1 pp
—
−15.0 pp
—
−2.3 pp
—
+3.7 pp
+5.3 pp
+3.7 pp
+4.1 pp
+2.0 pp
+1.4 pp
0.0 pp
+2.5 pp
Gland Pharma Ltd · GLAND
—
—
—
—
−4.9 pp
—
−8.3 pp
—
−4.8 pp
—
−0.5 pp
—
−0.4 pp
+0.7 pp
−1.5 pp
−0.2 pp
+0.2 pp
+0.8 pp
+2.1 pp
—
Granules India Ltd · GRANULES
—
—
—
—
+0.5 pp
—
+4.0 pp
—
−4.0 pp
—
−4.9 pp
—
+1.0 pp
+0.6 pp
−2.0 pp
−4.8 pp
−3.8 pp
−1.5 pp
−1.1 pp
+1.2 pp
Laurus Labs Ltd · LAURUSLABS
—
—
—
—
−9.1 pp
—
−2.6 pp
—
−13.8 pp
—
−17.3 pp
—
−7.2 pp
0.0 pp
+3.3 pp
+8.7 pp
+9.8 pp
+13.5 pp
+8.1 pp
+8.9 pp
Neuland Laboratories Ltd · NEULANDLAB
—
—
—
—
+1.9 pp
—
+10.8 pp
—
+17.1 pp
—
+8.5 pp
—
−6.0 pp
−8.2 pp
−13.2 pp
−20.8 pp
−9.2 pp
−14.2 pp
+6.5 pp
—
OneSource Specialty Pharma Ltd · ONESOURCE
—
—
—
—
—
—
—
—
—
—
—
—
—
—
+17.6 pp
+35.7 pp
+4.5 pp
+2.6 pp
−2.5 pp
—
Piramal Pharma Ltd · PPLPHARMA
—
—
—
—
—
—
−7.2 pp
—
−3.5 pp
+3.2 pp
+5.3 pp
—
+5.8 pp
+3.1 pp
+1.1 pp
+0.5 pp
−3.2 pp
−3.8 pp
−4.6 pp
—
Sai Life Sciences Ltd · SAILIFE
—
—
—
—
—
—
—
—
—
—
—
—
—
—
−0.5 pp
—
+1.7 pp
+6.7 pp
+5.5 pp
—
Shilpa Medicare Ltd · SHILPAMED
—
—
—
—
−0.1 pp
—
−5.6 pp
—
−0.2 pp
—
+5.7 pp
—
+4.3 pp
+4.1 pp
+2.0 pp
+0.7 pp
+1.7 pp
+0.5 pp
+3.6 pp
—
Syngene International Ltd · SYNGENE
—
—
—
—
+1.1 pp
—
+3.3 pp
—
+3.0 pp
—
−0.4 pp
—
−4.0 pp
−1.5 pp
−1.5 pp
+0.3 pp
+0.9 pp
−4.2 pp
−1.8 pp
—
11 · compare level, then change
Valuation Against Growth & Quality
IOL Chemicals & Pharmaceuticals Ltd has the lowest PEG among the 24 Pharma - API & CRAMS companies compared here, at 0.66×. Neuland Laboratories Ltd is next at 1.05×. The same company also holds the lowest P/E, at 27.5×. 16 of 24 companies report a comparable reading, the latest through Jun 2026.
What the numbers say: IOL Chemicals & Pharmaceuticals Ltd has the lowest comparable PEG at 0.66×, 37.1% below Neuland Laboratories Ltd. Only 16 of 24 companies have earnings and growth steady enough for the ratio to mean anything, so no broad “cheapest stock” conclusion is defensible unless the current multiple, own-history position and growth durability agree.
LeaderIOL Chemicals & Pharmaceuticals Ltd · 0.66×
Gap37.1% versus #2 · Neuland Laboratories Ltd
Persistence0/8 recent comparable periods
Coverage16/24 companies · 90 observations
Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.
This conclusion weakens if: The next two comparable reports reverse the current p/e signal.
PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.
PEGlowest PEG
P/Elowest P/E
Valuation · company comparison
16/24 level · 22/24 change
All-company data · latest reported quarter
| Company | PEG | P/E | Reported |
|---|---|---|---|
| Anthem Biosciences Ltd ANTHEM | 12.2 | 71.0 | Jun 2026 |
| Piramal Pharma Ltd PPLPHARMA | 11.2 | 307.1 | Jun 2026 |
| Syngene International Ltd SYNGENE | 7.9 | 46.5 | Jun 2026 |
| Shilpa Medicare Ltd SHILPAMED | 6.9 | 47.9 | Jun 2026 |
| Concord Biotech Ltd CONCORDBIO | 5.7 | 39.1 | Jun 2026 |
| Sai Life Sciences Ltd SAILIFE | 3.5 | 72.9 | Jun 2026 |
| Divis Laboratories Ltd DIVISLAB | 3.5 | 68.0 | Jun 2026 |
| Hikal Ltd HIKAL | 3.4 | 73.1 | Jun 2026 |
| Laurus Labs Ltd LAURUSLABS | 3.3 | 87.5 | Jun 2026 |
| Supriya Lifescience Ltd SUPRIYA | 3.1 | 35.7 | Jun 2026 |
| Dishman Carbogen Amcis Ltd DCAL | 2.7 | 26.9 | Jun 2026 |
| Morepen Laboratories Ltd MOREPENLAB | 1.7 | 39.1 | Jun 2026 |
| SMS Pharmaceuticals Ltd SMSPHARMA | 1.5 | 34.6 | Jun 2026 |
| Gland Pharma Ltd GLAND | 1.5 | 36.5 | Jun 2026 |
| Blue Jet Healthcare Ltd BLUEJET | 1.4 | 36.9 | Jun 2026 |
| Granules India Ltd GRANULES | 1.3 | 31.0 | Jun 2026 |
| Jubilant Pharmova Ltd JUBLPHARMA | 1.2 | 35.4 | Jun 2026 |
| Solara Active Pharma Sciences Ltd SOLARA | 1.1 | -276.6 | Jun 2026 |
| Neuland Laboratories Ltd NEULANDLAB | 1.1 | 63.3 | Jun 2026 |
| IOL Chemicals & Pharmaceuticals Ltd IOLCP | 0.7 | 26.9 | Jun 2026 |
| Acutaas Chemicals Ltd 543349 | — | 75.8 | Jun 2026 |
| OneSource Specialty Pharma Ltd ONESOURCE | — | 684.8 | Jun 2026 |
| Cohance Lifesciences Ltd COHANCE | — | 88.8 | Jun 2026 |
| Windlas Biotech Ltd WINDLAS⚠ unverified | — | 24.1 | Mar 2026 |
Full 20-quarter history · every available company
PEG · reported quarter history
Showing the 12 largest of 20 companies with a series here. The remaining 8 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Anthem Biosciences Ltd · ANTHEM
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
12.2
—
—
—
Concord Biotech Ltd · CONCORDBIO
—
—
—
—
—
—
—
—
—
—
—
5.8
3.8
1.8
7.5
2.1
—
—
5.7
—
Divis Laboratories Ltd · DIVISLAB
2.3
2.7
—
0.7
0.7
0.8
—
—
—
—
—
—
6.5
2.2
1.5
2.2
1.7
—
2.8
3.5
Gland Pharma Ltd · GLAND
2.1
1.9
4.8
1.7
3.6
—
—
—
—
—
—
—
—
—
—
—
6.3
2.4
1.5
—
Granules India Ltd · GRANULES
—
—
—
—
—
0.6
0.8
0.5
3.5
—
—
—
2.0
1.2
1.4
1.4
—
—
0.9
1.3
Jubilant Pharmova Ltd · JUBLPHARMA
—
—
—
—
—
—
—
—
—
—
—
—
—
1.2
—
—
—
—
—
—
Laurus Labs Ltd · LAURUSLABS
—
—
3.0
—
—
0.7
—
—
—
—
—
—
—
—
—
—
—
—
3.3
—
Neuland Laboratories Ltd · NEULANDLAB
—
—
2.4
—
—
—
—
—
—
—
—
0.6
1.1
—
—
—
—
—
—
—
Piramal Pharma Ltd · PPLPHARMA
—
—
—
—
—
—
—
—
—
—
—
—
—
—
11.2
—
—
—
—
—
Sai Life Sciences Ltd · SAILIFE
—
—
—
—
—
—
—
—
—
—
—
—
—
3.7
2.7
—
—
—
3.5
—
Shilpa Medicare Ltd · SHILPAMED
—
6.9
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
Syngene International Ltd · SYNGENE
4.5
4.6
5.3
5.5
9.9
9.0
7.8
6.0
4.2
3.2
9.6
4.8
—
—
—
—
7.9
—
—
—
P/E · reported quarter history
Showing the 12 largest of 24 companies with a series here. The remaining 12 are complete in the plain-text rendition and the trace payload — nothing is dropped from the data, only from this grid.
Acutaas Chemicals Ltd · 543349
74.9
62.2
51.5
43.6
45.5
47.1
41.9
55.6
51.0
54.6
57.6
70.2
104.5
94.3
80.3
58.9
58.8
60.4
72.6
75.8
Anthem Biosciences Ltd · ANTHEM
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
94.2
70.7
73.2
71.0
Cohance Lifesciences Ltd · COHANCE
36.6
31.5
34.3
26.7
25.2
29.2
31.7
30.1
33.7
42.6
46.5
68.1
115.7
94.7
69.7
48.2
48.1
36.9
31.6
88.8
Divis Laboratories Ltd · DIVISLAB
66.2
58.1
46.0
33.0
31.7
30.3
31.3
52.2
67.7
77.9
66.1
76.3
86.5
85.0
74.2
80.7
65.5
68.7
62.9
68.0
Gland Pharma Ltd · GLAND
63.1
56.7
44.2
35.8
31.6
25.2
21.1
21.4
35.3
43.2
43.8
38.9
40.7
43.1
37.2
42.0
41.9
34.5
32.9
36.5
Granules India Ltd · GRANULES
14.3
17.5
18.4
15.4
20.4
16.3
14.1
14.1
19.8
24.9
26.4
29.5
27.4
29.1
24.6
25.1
26.2
29.3
27.9
31.0
Laurus Labs Ltd · LAURUSLABS
31.1
28.6
35.4
30.3
32.9
23.2
17.2
25.0
37.7
63.0
112.4
141.5
168.9
241.4
165.3
133.9
88.3
85.6
64.5
87.5
Neuland Laboratories Ltd · NEULANDLAB
26.6
27.1
23.7
21.1
26.9
25.7
23.0
22.2
22.0
25.5
25.6
32.0
51.2
66.6
64.5
77.7
136.0
98.2
86.4
63.3
OneSource Specialty Pharma Ltd · ONESOURCE
—
—
—
—
—
—
—
—
—
—
—
—
—
—
-1,115.8
—
527.6
150.3
540.0
684.8
Piramal Pharma Ltd · PPLPHARMA
—
—
—
—
—
—
-43.8
—
-101.0
-551.0
957.0
683.6
719.7
578.5
561.9
294.0
288.8
307.1
—
—
Sai Life Sciences Ltd · SAILIFE
—
—
—
—
—
—
—
—
—
—
—
—
—
113.2
93.2
66.1
62.9
66.2
60.9
72.9
Syngene International Ltd · SYNGENE
65.3
61.7
57.4
54.1
53.9
54.9
55.0
66.1
66.7
55.9
55.5
55.0
74.5
74.2
61.2
54.8
48.4
56.3
40.9
46.5
12 · before the conclusion, check the blind spots
What can make this comparison misleading?
This Pharma - API & CRAMS comparison names 6 specific ways its own evidence can mislead, all listed below. All 24 companies here report on comparable dates, so no rank carries a stale marker. 1 draws at least one figure from a second feed with too little overlap to cross-check. 1 has second-feed figures withheld because the two sources disagree.
Keep these limits visible
- A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
- A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
- The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
- An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
- 1 company draws at least one figure from a second data feed with too little overlapping history to cross-check against the primary source; it is marked unverified wherever that figure appears.
- 1 company is missing from the second-feed metrics by decision, not by absence: the two sources disagree, so nothing from the second is drawn. Read those rows as narrower evidence, never as a weaker business.
13 · evidence and freshness
How was this comparison built?
This comparison is built from the reported filings of 24 Pharma - API & CRAMS companies, normalized to a common ₹ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Jun 2026 and market data through 2026-08-14.
FundamentalsThrough Jun 2026 · up to 20 quarters per company
Market dataThrough 2026-08-14 · weekly price and relative-strength history
Derived metricsGrowth, changes and PEG are calculated only when their inputs are comparable.
Score confidenceMissing and stale evidence reduces confidence and pulls the 0–100 research-priority score toward neutral.
Source standing21 cross-checked · 2 unverified · 1 withheld, of 24 graded companies.
How a second data feed is admitted, and what happens when it disagrees
A second feed is read only after its reported income is matched against the primary source on at least three overlapping periods. Where the two agree the figures fill silently. Where there is too little shared history to compare, the figures are still drawn — they are the only evidence there is — and marked ⚠ unverified everywhere they appear. Where the two are known to disagree, nothing from the second feed is drawn and the affected company is named under the chart it is missing from.
14 · questions investors ask, short speakable answers
Pharma - API & CRAMS company comparison FAQs
These 24 answers restate the Pharma - API & CRAMS comparison above in question form. Every one is computed from the same 24 companies and the same reported filings as the rankings and charts, current through Jun 2026. Price and relative-strength answers run through 2026-08-14. Nothing here is estimated, and none of it is a recommendation.
Is the Pharma - API & CRAMS sector outperforming NIFTY 500?
Pharma - API & CRAMS has outperformed NIFTY 500 by 20.8% over 52 weeks and 16.8% over 13 weeks. 17 of 24 covered companies beat NIFTY on Mansfield relative strength, while 9 of 24 beat the sector itself.
Which Pharma - API & CRAMS company is largest by revenue?
Divis Laboratories Ltd leads with revenue of ₹11,230 crore, based on 24 of 24 comparable companies through Jun 2026.
Which Pharma - API & CRAMS company is growing fastest?
Neuland Laboratories Ltd has the fastest current revenue growth at 78.3%, across 24 of 24 comparable companies.
Which Pharma - API & CRAMS company has the strongest 4-Factor Sector Score?
Neuland Laboratories Ltd ranks first at 82.7/100 with 100% evidence confidence. The score prioritizes research; it is not a buy recommendation.
Which Pharma - API & CRAMS company has the lowest comparable PEG?
IOL Chemicals & Pharmaceuticals Ltd has the lowest comparable PEG at 0.66, among 16 of 24 companies whose earnings and growth are steady enough for the ratio to mean anything.
How much history does this Pharma - API & CRAMS comparison include?
The page compares up to 20 reported quarters per company for fundamentals, returns and valuation, ending Jun 2026. Missing observations remain blank rather than being estimated.
How is the 4-Factor Sector Score calculated?
The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.
Is there a Nifty Pharma - API & CRAMS index?
NSE India maintains Nifty indices for several broad sector categories — Nifty Bank, Nifty IT, Nifty Pharma and others — but not for every sub-sector grouping on this site. Whether or not an official Nifty index covers Pharma - API & CRAMS, this page builds its own equal-weight basket of 24 listed Pharma - API & CRAMS companies — one company, one vote, regardless of market value — so no single large company dominates the reading. Figures are as of Jun 2026.
Which are the best Pharma - API & CRAMS stocks in India?
Ranked by this page's four-factor score, Neuland Laboratories Ltd places first among 24 listed Pharma - API & CRAMS companies, followed by IOL Chemicals & Pharmaceuticals Ltd. That is a ranking of published data — earnings, quality, valuation and market behaviour as of Jun 2026 — and not a recommendation; Sector Alpha is not registered with SEBI as an investment adviser.
How many Pharma - API & CRAMS stocks are listed in India?
This comparison covers 24 listed Pharma - API & CRAMS companies in India, each above the size floor the site applies, with 20 quarters of reported figures per company where the filings exist. The full ranked list is on this page, as of Jun 2026.
Which Pharma - API & CRAMS company is the biggest?
Divis Laboratories Ltd is the largest, with trailing-twelve-month revenue of ₹11,230 crore, ahead of Piramal Pharma Ltd at ₹9,206 crore. That covers 24 of 24 companies with comparable reporting through Jun 2026.
Which Pharma - API & CRAMS company has the best profit margins?
Divis Laboratories Ltd has the highest operating margin at 41%, from 24 of 24 comparable companies. Neuland Laboratories Ltd shows the biggest recent improvement, at +23 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.
Which Pharma - API & CRAMS company makes the most profit?
Divis Laboratories Ltd earns the most, at ₹2,925 crore of trailing-twelve-month net profit, from 24 of 24 comparable companies. Acutaas Chemicals Ltd has the fastest profit growth at the ≥100% scoring cap, though growth off a small or recovering profit base overstates how much has actually changed.
Which Pharma - API & CRAMS company earns the highest return on capital?
Acutaas Chemicals Ltd leads on return on capital employed at 31.6%, across 24 of 24 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.
Which Pharma - API & CRAMS stock is the cheapest?
On PEG — where a LOWER number is cheaper — IOL Chemicals & Pharmaceuticals Ltd screens cheapest at 0.66×. Only 16 of 24 companies have earnings and growth steady enough for the ratio to mean anything, so this is not a sector-wide "cheapest stock" verdict. Cheap on a multiple is a reason to investigate, never a reason to buy on its own.
Is the Pharma - API & CRAMS sector beating the market?
Pharma - API & CRAMS has outperformed NIFTY 500 by 20.8% over the last 52 weeks and 16.8% over 13 weeks, measured on an equal-weight index of its current members. Inside the sector, 17 of 24 covered companies are beating the market on their own. Sector strength does not transfer evenly to every stock in it.
Which Pharma - API & CRAMS stock has the strongest price momentum?
Shilpa Medicare Ltd has the strongest relative strength against NIFTY 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.
Which Pharma - API & CRAMS company scores highest for research priority?
Neuland Laboratories Ltd scores 82.7 out of 100 with 100% evidence confidence, from 33.6 points on growth and earnings, 19.7 on capital efficiency, 11.8 on valuation and 17.6 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.
How many Pharma - API & CRAMS companies does this comparison cover, and over what period?
It compares 24 listed companies over up to 20 reported quarters of fundamentals, ending Jun 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.
What is the total market cap of the Pharma - API & CRAMS sector?
The 24 Pharma - API & CRAMS companies on this page carry ₹6,93,081 crore of combined market value. Divis Laboratories Ltd is the largest at ₹2,25,038 crore, about 32% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-08-18.
What is the Pharma - API & CRAMS sector's P/E ratio?
The median price-to-earnings ratio across the 24 Pharma - API & CRAMS companies on this page is 56.5×, measured on the 22 that report a comparable figure. A sector-level history for this multiple is not held here, so this is a cross-section of today, not a comparison with the sector’s own past. Figures are as of 2026-08-18.
How is the Pharma - API & CRAMS sector performing?
17 of the 24 covered Pharma - API & CRAMS companies are beating NIFTY 500 on Mansfield relative strength. The sector itself is 20.8% ahead of NIFTY 500 over 52 weeks on an equal-weight index of its current members. Readings are as of 2026-08-18.
Why are some values on this page blank?
A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.
Is this investment advice?
No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.